Toyoaki Hida

ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 12

Top Venues

Cancer science

Therapeutic advances in respiratory disease

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Makoto Nishio, Terufumi Kato, Ryo Toyozawa, Toyoaki Hida
Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors. Targeted oncology 17 (5) (2022)
Nobuhiro Kanaji, Junichi Shimizu, Kenichiro Sakai, Yutaka Ueda, Hiroshi Miyawaki, Naohiro Watanabe, Takehiro Uemura, Toyoaki Hida, Takuya Inoue, Naoki Watanabe, Yasuhiro Oohara, Hiroaki Dobashi, Mikiya Kato, Norimitsu Kadowaki
Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. Therapeutic advances in respiratory disease 14 (2021)
Takashi Seto, Kadoaki Ohashi, Shunichi Sugawara, Makoto Nishio, Masayuki Takeda, Keisuke Aoe, Sanae Moizumi, Satoshi Nomura, Takeshi Tajima, Toyoaki Hida
Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study. Cancer science 112 (4) (2021)
Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science 112 (12) (2021)
Yusuke Kagawa, Hiromi Furuta, Takehiro Uemura, Naohiro Watanabe, Junichi Shimizu, Yoshitsugu Horio, Hiroaki Kuroda, Yoshitaka Inaba, Takeshi Kodaira, Katsuhiro Masago, Shiro Fujita, Akio Niimi, Toyoaki Hida
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. Cancer science 111 (12) (2020)
Takashi Seto, Hidetoshi Hayashi, Miyako Satouchi, Yasushi Goto, Seiji Niho, Naoyuki Nogami, Toyoaki Hida, Toshiaki Takahashi, Jun Sakakibara-Konishi, Masahiro Morise, Takashi Nagasawa, Mie Suzuki, Masayuki Ohkura, Kei Fukuhara, Holger Thurm, Gerson Peltz, Makoto Nishio
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. Cancer science 111 (10) (2020)
Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science 111 (12) (2020)
Kentaro Ito, Kenta Murotani, Akihito Kubo, Eiji Kunii, Hirokazu Taniguchi, Joe Shindoh, Kazuhiro Asada, Kazuyoshi Imaizumi, Kosuke Takahashi, Masato Karayama, Motoyasu Okuno, Naoki Inui, Osamu Hataji, Sayako Morikawa, Shunsaku Hayai, Takafumi Suda, Takashi Abe, Takeshi Tsuda, Teppei Yamagichi, Tomoki Kimura, Yuko Oya, Tatsuya Yoshida, Toyoaki Hida
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data. Cancer science 111 (10) (2020)
Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L Vowler, Tetsuya Mitsudomi
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Cancer science 110 (9) (2019)
Toyoaki Hida
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety. Therapeutic advances in respiratory disease 12 (2019)
Koichi Azuma, Makoto Nishio, Hidetoshi Hayashi, Katsuyuki Kiura, Miyako Satouchi, Shunichi Sugawara, Toyoaki Hida, Yasuo Iwamoto, Akira Inoue, Koji Takeda, Satoshi Ikeda, Tomoki Nakagawa, Kentaro Takeda, Seitaro Asahina, Kanji Komatsu, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Cancer science 109 (8) (2018)
Toyoaki Hida, Takashi Seto, Hidehito Horinouchi, Makoto Maemondo, Masayuki Takeda, Katsuyuki Hotta, Fumihiko Hirai, Young Hak Kim, Shingo Matsumoto, Masayuki Ito, Koichi Ayukawa, Kota Tokushige, Masataka Yonemura, Testuya Mitsudomi, Makoto Nishio
Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. Cancer science 109 (9) (2018)

Toyoaki Hida.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Toyoaki Hida